BioWorld

May 7, 2008

View Archived Issues

Apoptos Targeting Cell Death with $28M Series A Financing

Year-old Apoptos Inc. is raising $28 million in its first major funding round since being established in June 2007 by venture firms Venrock and ARCH Ventures based on technology targeting programmed cell death. (BioWorld Today) Read More

FDA Panel Advises Against Wider Marketing of Fentora

Read More

New Data on MedImmune, AVI BioPharma RSV Drugs

Read More

Merck Cost-Cutting Could Be Boon for Biotech Firms

Read More

Pfizer Pullout Sends NicOx Shares Down

Read More

Other News To Note

Read More

Clinic Roundup

Read More